Explicyte poster at ESMO IO Congress 2019
12 / 17 / 2019
"Comprehensive assessment of anti-tumor PDL1 blockade effect in a sarcoma mouse model"
12 2019
Scientific communications
11 2019
Antibody-dependent cell-mediated cytotoxicity (ADCC) assay for in vitro testing
11 / 21 / 2019
See our case study below or download our white paper!
Many cells of the innate immunity work in concert with the adaptive immune system to effectively afford protection.
10 2019
In vivo syngeneic tumor models for novel drug assessment and MoA deciphering in a cost-saving way
10 / 09 / 2019
How about an opportunity to assess your compounds in a comprehensive and cost-effective manner?
09 2019
Involvement of CD8 T cells in the tumor growth control and in the response to PD1 and PDL1 antibodies
09 / 12 / 2019
Immunotherapy-based anti-cancer strategies such as immune checkpoint inhibitors promote antitumor immune response driven by the mobilization of effector immune cell activity and/or reversal of immunosuppressive mechanisms.
06 2019
In vitro assessment of functional response to PD1 blockade
06 / 27 / 2019
Relying on our validated in vitro immune cell activation assay based on the HTRF quantitation of key cytokine release, we recently documented functional characterization of PD1 blockade.
05 2019
Combination of in vivo monitoring and flow cytometry-based immunoprofiling on syngeneic tumor models
05 / 24 / 2019
Syngeneic tumor models were becoming invaluable for preclinical development and evaluation of immuno-based therapies in the presence of a functional immunocompetent system. Explicyte is providing a series of syngeneic mouse models including subcutaneous and orthotopic models, which were fully characterized in terms of their responsiveness to immune checkpoint inhibitors (ICI) and their immune infiltration features using a high throughput-compatible flow cytometry platform.
04 2019
Shuttle session: M2 Macrophage Suppression Assay for immunotherapeutic screening
04 / 09 / 2019
We are proud to offer a first in vitro shuttle session on our newly validated M2 macrophage suppression assay, which will take place early June, 2019 – thereby providing an opportunity to timely and cost-effectively assess novel immunotherapeutics.
03 2019
M2 Macrophage Suppression Assay
03 / 13 / 2019
Our newly validated M2 suppression assay based on i) the co-culture of autologous monocyte-derived M2 macrophages and activated CD4+ T cells (or PBMCs) and on ii) the quantitation of IFNg levels as surrogate of T cell activation, is specifically designed to assess new immunotherapeutics for their modulatory activity on the phenotype and function of M2 macrophages.
Candidate compounds can thus be evaluated as single agents or in combinatorial treatments, for their potential to repolarize / switch M2 macrophages and to antagonize M2-mediated T cell suppression.
02 2019
Intratumoral microdialysis-based approach to assess tumor immunometabolism & specific immunometabolic pathways-targeting
02 / 20 / 2019
Syngeneic tumor models were becoming invaluable for preclinical development and evaluation of immuno-based therapies. Nevertheless, the immunometabolic features of these tumors models, which may likely underlie responsiveness to immunotherapies, are still not well understood and become thus primordial to be defined for tumor model characterization and selection of the appropriate ones, for target validation, drug development, and assessment of the efficacy potential of drug candidates.
01 2019
New shuttle session with our in vivo syngeneic subcutaneous tumor models – for cost-saving efficacy studies
01 / 17 / 2019
Explicyte is planning a new in vivo shuttle session by early March, thereby providing an opportunity to cost-effectively assess your drug candidates in our well-suited immunocompetent syngeneic subcutaneously-implanted tumor models, over studies where a significant cost part will be supported by ourselves.